1. Scrip
  2. >>Business
  3. >>Deals

Tech Transfer Roundup: Deerfield, Broad Institute Alliance Selects Two Cancer Programs

 
• By Joseph Haas

An alliance of Deerfield and the Broad Institute to accelerate research into high-mortality diseases identifies its first two research projects, while Janssen and UPenn look into gene therapy for Alzheimer's disease.

Tech Transfer regular column feature image

Below is Scrip’s monthly roundup, including information from Strategic Transactions, of recent technology transfer agreements between companies and academic or other research institutions.

Deerfield Management and the Broad Institute have selected their first two projects – one aimed at understanding and dealing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Deal Watch: GSK To Tap AN2’s Boron Chemistry Approach In Tuberculosis R&D

 
• By Joseph Haas and Sushmita Panda

Also deals involving Lyell/Innovative Cellular, Lilly/Ailux, Dynavax/Vaxart, AVEO/HiberCell, Incyte/Prelude, AmacaThera/Pacira, Roche/Manifold and Chromatin/Purespring.

Jefferies Conference 2025: Five Themes To Follow

 
• By Andrew McConaghie

The investor event will bring deal-hungry big pharma and biotech execs together but input from the FDA’s unsettled leadership will be missing this year.

Bayer Boss Cautious On Late-Stage Deals Despite Beyonttra Success

 
• By Kevin Grogan

CEO Bill Anderson tells Scrip that the German group looks at potential in-licensing opportunities across every stage of the pipeline “but as you know, good value is a lot harder to come by in the late stage.”

A Week Is A Long Time In Biotech, Just Ask Galecto

 
• By Kevin Grogan

A long time on the ropes, the US firm is now well-financed to advance potential candidates for essential thrombocythemia and myelofibrosis into the clinic.

More from Business

Investors Shower Chinese In Vivo CAR-T Biotechs With Quick Cash

 
• By Dexter Jie Yan

Byterna, Starna, Vivacta and DeliNova ride surging investor sentiment on in vivo CAR-T assets to secure venture funding.

MASH Updates: Sagimet, Altimmune, GSK Discuss Development Plans At AASLD

 
• By Joseph Haas

Sagimet may shift focus to later-stage MASH while it lines up Phase III financing. Altimmune expects its dual agonist to show efficacy and tolerability, while GSK is readying efimosfermin as the third FGF21 analog into Phase III for MASH.

Finance Watch: Public Biopharma Company Financings Surged Globally In Q3

 
• By Mandy Jackson

Public Company Financings: Biomedtracker’s third quarter report shows a big jump from Q2 in follow-on offerings, private placements and debt. Also, Evommune brings the US biopharma IPO tally for 2025 to a dozen and Merck’s Blackstone deal gives it $700m to develop a key ADC asset.